Skip to main content

Ligand-based target predictions in ChEMBL



In case you haven't noticed, ChEMBL_18 has arrived. As usual, it brings new additions, improvements and enhancements both on the data/annotation, as well as on the interface. One of the new features is the target predictions for small molecule drugs. If you go to the compound report card for such a drug, say imatinib or cabozantinib, and scroll down towards the bottom of the page, you'll see two tables with predicted single-protein targets, corresponding to the two models that we used for the predictions. 


 - So what are these models and how were they generated? 

They belong to the family of the so-called ligand-based target prediction methods. That means that the models are trained using ligand information only. Specifically, the model learns what substructural features (encoded as fingerprints) of ligands correlate with activity against a certain target and assign a score to each of these features. Given a new molecule with a new set of features, the model sums the individual feature scores for all the targets and comes up with a sorted list of likely targets with the highest scores. Ligand-based target prediction methods have been quite popular over the last years as they have been proved useful for target-deconvolution and mode-of-action prediction of phenotypic hits / orphan actives. See here for an example of such an approach and here for a comprehensive review.


 - OK, and how where they generated?

As usual, it all started with a carefully selected subset of ChEMBL_18 data containing pairs of compounds and single-protein targets. We used two activity cut-offs, namely 1uM and a more relaxed 10uM, which correspond to two models trained on bioactivity data against 1028 and 1244 targets respectively. KNIME and pandas were used for the data pre-processing. Morgan fingerprints (radius=2) were calculated using RDKit and then used to train a multinomial Naive Bayesian multi-category scikit-learn model. These models then were used to predict targets for the small molecule drugs as mentioned above. 


 - Any validation? 

Besides more trivial property predictions such as logP/logD, this is the first time ChEMBL hosts non experimental/measured data - so this is a big deal and we wanted to try and do this right. First of all, we did a 5-fold stratified cross-validation. But how do you assess a model with a many-to-many relationship between items (compounds) and categories (targets)? For each compound in each of the 5 20% test sets, we got the top 10 ranked predictions. We then checked whether these predictions agree with the known targets for that compound. Ideally, the known target should be correctly predicted at the 1st position of the ranked list, otherwise at the 2nd position, the 3rd and so on. By aggregating over all compounds of all test sets, you get this pie chart:


This means that a known target is correctly predicted by the model at the first attempt (Position 1 in the list of predicted targets) in ~69% of the cases. Actually, only 9% of compounds in the test sets had completely mis-predicted known targets within the top 10 predictions list (Found above 10). 

This is related to precision but what about recall of know targets? here's another chart:



This means that, on average, by considering the top 10 most likely target predictions (<1% of the target pool), the model can correctly predict around ~89% of a compound's known single protein targets. 

Finally, we compared the new open source approach (right) to an established one generated with a commercial workflow environment software (left) using the same data and very similar descriptors:


If you manage to ignore for a moment the slightly different colour coding, you'll see that their predictive performance is pretty much equivalent.

 - It all sounds good, but can I get predictions for my own compounds?

We could provide the models and examples in IPython Notebook on how to use these on another blog post that will follow soon. There are also plans for a publicly available target prediction web service, something like SMILES to predicted targets. Actually, if you would be interested in this, or if you have any feedback or suggestions for the target prediction functionality, let us know

George

Comments

Unknown said…
Very nice post, cheers!
Unknown said…
Any thoughts on the domain of validity in chemical space of these models? Do you expect them to work well across all of chembl, and if not can you specify what compounds they will fail on?
Unknown said…
Thank You for the very interesting work! I have some questions. First of all, i don't quite understand your validation technique. For example: a compound has 3 targets. Target 1 was found at the first position; target 2 was found at the second position and target 3 was not found in top 10 list of predictions. What did you do exactly in similar cases? Second, how many compounds are there in your training set?

Popular posts from this blog

Here's a nice Christmas gift - ChEMBL 35 is out!

Use your well-deserved Christmas holidays to spend time with your loved ones and explore the new release of ChEMBL 35!            This fresh release comes with a wealth of new data sets and some new data sources as well. Examples include a total of 14 datasets deposited by by the ASAP ( AI-driven Structure-enabled Antiviral Platform) project, a new NTD data se t by Aberystwyth University on anti-schistosome activity, nine new chemical probe data sets, and seven new data sets for the Chemogenomic library of the EUbOPEN project. We also inlcuded a few new fields that do impr ove the provenance and FAIRness of the data we host in ChEMBL:  1) A CONTACT field has been added to the DOCs table which should contain a contact profile of someone willing to be contacted about details of the dataset (ideally an ORCID ID; up to 3 contacts can be provided). 2) In an effort to provide more detailed information about the source of a deposited dat...

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by...

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding ...

Improved querying for SureChEMBL

    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never ...

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen...